Yes, clonidine is available as a transdermal patch for extended-release delivery.
How does the clonidine patch work?
The patch, marketed as Catapres-TTS, releases clonidine steadily through the skin over 7 days to treat high blood pressure. Apply it to a hairless area like the upper arm or chest, and replace weekly. It reduces dosing frequency compared to oral forms.[1]
What strengths are available?
Patches come in four doses: 0.1 mg/day, 0.2 mg/day, 0.3 mg/day, and 0.4 mg/day (the latter as a matrix-style patch from Mylan). Generic versions exist from manufacturers like Actavis and Par.[2][3]
Can you use it for anything besides blood pressure?
Doctors sometimes prescribe it off-label for opioid withdrawal, ADHD, or hot flashes, though evidence varies. Patches provide consistent levels, which helps in these cases, but oral clonidine remains first-line for most non-hypertension uses.[4]
What side effects do users report?
Common issues include skin irritation or rash at the site (use hydrocortisone cream if needed), drowsiness, dry mouth, or dizziness. Avoid abrupt removal to prevent rebound hypertension. Patches may cause less initial sedation than pills.[1][5]
How much do clonidine patches cost?
Generic patches run $30–$100 for a 4-week supply without insurance, depending on dose and pharmacy. Brand Catapres-TTS is pricier at $200+. GoodRx coupons often cut costs by 70%.[6]
Are there patents still active on clonidine patches?
Original Catapres-TTS patents expired decades ago (clonidine itself patented in 1964, U.S. patent 3,202,660). Generics launched in the 1990s. Check DrugPatentWatch.com for any formulation-specific expirations or litigation—none block generics currently.[7]
[1] DailyMed: Catapres-TTS (clonidine) patch label, NIH.
[2] FDA Orange Book: Approved drug products with therapeutic equivalence.
[3] Mylan generics catalog.
[4] American Academy of Family Physicians: Clonidine review (2015).
[5] Mayo Clinic: Clonidine side effects.
[6] GoodRx pricing data (2023 averages).
[7] DrugPatentWatch.com: Catapres-TTS patents.